Source: BMC cancer [BMC Cancer] 2025 Jul 25; Vol. 25 (1), pp. 1220. Date of Electronic Publication: 2025 Jul 25.Publisher: BioMed Central Country of Publication: England NLM ID: 100967800 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2407

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

A randomized, open-label, phase 3 trial of pembrolizumab plus epacadostat versus sunitinib or pazopanib as first-line treatment for metastatic renal cell carcinoma (KEYNOTE-679/ECHO-302).

Authors : Lara PN Jr; University of California Davis Comprehensive Cancer Center, University of California Davis, 4501 X Street, Davis, Sacramento, CA, 95817, USA. .; Villanueva L

Subjects: Antibodies, Monoclonal, Humanized*/Antibodies, Monoclonal, Humanized*/Antibodies, Monoclonal, Humanized*/administration & dosage ; Antibodies, Monoclonal, Humanized*/Antibodies, Monoclonal, Humanized*/Antibodies, Monoclonal, Humanized*/therapeutic use ; Antibodies, Monoclonal, Humanized*/Antibodies, Monoclonal, Humanized*/Antibodies, Monoclonal, Humanized*/adverse effects

Source: BMC cancer [BMC Cancer] 2024 Jul 25; Vol. 23 (Suppl 1), pp. 1253. Date of Electronic Publication: 2024 Jul 25.Publisher: BioMed Central Country of Publication: England NLM ID: 100967800 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2407

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

[The efficacy and safety of anlotinib combined with niraparib in treating patients with platinum-resistant recurrent ovarian cancer].

Authors : Yang M; Department of Gynecology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen 518117, China.; Wang JJ

Subjects: Indazoles*/Indazoles*/Indazoles*/adverse effects ; Indazoles*/Indazoles*/Indazoles*/therapeutic use ; Ovarian Neoplasms*/Ovarian Neoplasms*/Ovarian Neoplasms*/drug therapy

Source: Zhonghua zhong liu za zhi [Chinese journal of oncology] [Zhonghua Zhong Liu Za Zhi] 2024 Jul 23; Vol. 46 (7), pp. 696-702.Publisher: Chinese Medical Association Country of Publication: China NLM ID: 7910681 Publication Model: Print Cited Medium: Print ISSN: 0253-3766

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

Comparing niraparib versus platinum-taxane doublet chemotherapy as neoadjuvant treatment in patients with newly diagnosed homologous recombination-deficient stage III/IV ovarian cancer: study protocol for cohort C of the open-label, phase 2, randomized controlled multicenter OPAL trial.

Authors : Belotte J; GSK, 1000 Winter Street North #3300, Waltham, MA, 02451, USA. .; Felicetti B

Subjects: Ovarian Neoplasms*/Ovarian Neoplasms*/Ovarian Neoplasms*/drug therapy ; Ovarian Neoplasms*/Ovarian Neoplasms*/Ovarian Neoplasms*/pathology ; Neoadjuvant Therapy*/Neoadjuvant Therapy*/Neoadjuvant Therapy*/adverse effects

Source: Trials [Trials] 2024 May 04; Vol. 25 (1), pp. 301. Date of Electronic Publication: 2024 May 04.Publisher: BioMed Central Country of Publication: England NLM ID: 101263253 Publication Model: Electronic Cited Medium: Internet ISSN: 1745-6215

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

Vulnerability to low-dose combination of irinotecan and niraparib in ATM-mutated colorectal cancer.

Authors : Vitiello PP; Department of Precision Medicine, Medical Oncology, Università degli Studi della Campania Luigi Vanvitelli, Naples, Campania, Italy.; Martini G

Subjects: Antineoplastic Combined Chemotherapy Protocols/Antineoplastic Combined Chemotherapy Protocols/Antineoplastic Combined Chemotherapy Protocols/*therapeutic use ; Colorectal Neoplasms/Colorectal Neoplasms/Colorectal Neoplasms/*drug therapy ; Indazoles/Indazoles/Indazoles/*therapeutic use

Source: Journal of experimental & clinical cancer research : CR [J Exp Clin Cancer Res] 2021 Jan 06; Vol. 40 (1), pp. 15. Date of Electronic Publication: 2021 Jan 06.Publisher: BioMed Central Country of Publication: England NLM ID: 8308647 Publication Model: Electronic Cited Medium: Internet ISSN: 1756-9966

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

Effect of Differences in Metabolic Activity of Melanoma Models on Response to Lonidamine plus Doxorubicin.

Authors : Nath K; Department of Radiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. .; Roman J

Subjects: Antineoplastic Combined Chemotherapy Protocols/Antineoplastic Combined Chemotherapy Protocols/Antineoplastic Combined Chemotherapy Protocols/*pharmacology ; Doxorubicin/Doxorubicin/Doxorubicin/*pharmacology ; Energy Metabolism/Energy Metabolism/Energy Metabolism/*drug effects

Source: Scientific reports [Sci Rep] 2018 Oct 02; Vol. 8 (1), pp. 14654. Date of Electronic Publication: 2018 Oct 02.Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101563288 Publication Model: Electronic Cited Medium: Internet ISSN:

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

A single-arm, phase II study of niraparib and bevacizumab maintenance therapy in platinum-sensitive, recurrent ovarian cancer patients previously treated with a PARP inhibitor: Korean Gynecologic Oncology Group (KGOG 3056)/NIRVANA-R trial.

Authors : Park J; Department of Obstetrics and Gynecology, Institute of Women's Life Medical Science, Yonsei University College of Medicine, Seoul, Korea.; Severance Biomedical Science Institute, Yonsei University College of Medicine, Seoul, Korea.

Subjects: Antineoplastic Combined Chemotherapy Protocols*/Antineoplastic Combined Chemotherapy Protocols*/Antineoplastic Combined Chemotherapy Protocols*/adverse effects ; Ovarian Neoplasms*/Ovarian Neoplasms*/Ovarian Neoplasms*/drug therapy ; Ovarian Neoplasms*/Ovarian Neoplasms*/Ovarian Neoplasms*/pathology

Source: Journal of gynecologic oncology [J Gynecol Oncol] 2022 Mar; Vol. 33 (2), pp. e12. Date of Electronic Publication: 2021 Dec 06.Publisher: Asian Society of Gynecologic Oncology Country of Publication: Korea (South) NLM ID: 101483150 Publication Model: Print-Electronic Cited Medium:

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

A Phase-2 Trial of Single Agent Axitinib as Maintenance Therapy Following First-Line Treatment With Modified FOLFOX/Bevacizumab in Patients With Metastatic Colorectal Cancer.

Authors : Bendell JC; a Sarah Cannon Research Institute , Nashville , Tennessee , USA.; b Tennessee Oncology PLLC , Nashville , Tennessee , USA.

Subjects: Antineoplastic Combined Chemotherapy Protocols/Antineoplastic Combined Chemotherapy Protocols/Antineoplastic Combined Chemotherapy Protocols/*therapeutic use ; Bevacizumab/Bevacizumab/Bevacizumab/*therapeutic use ; Colorectal Neoplasms/Colorectal Neoplasms/Colorectal Neoplasms/*drug therapy

Source: Cancer investigation [Cancer Invest] 2017 Jul 03; Vol. 35 (6), pp. 386-392. Date of Electronic Publication: 2017 Apr 20.Publisher: Taylor & Francis Country of Publication: England NLM ID: 8307154 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

Real-World Clinical Outcomes and Prognostic Factors for Patients with Advanced Angiosarcoma who Received Systemic Treatment.

Authors : Park C; Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea.; Kim M

Subjects: Antineoplastic Combined Chemotherapy Protocols/Antineoplastic Combined Chemotherapy Protocols/Antineoplastic Combined Chemotherapy Protocols/*therapeutic use ; Hemangiosarcoma/Hemangiosarcoma/Hemangiosarcoma/*mortality ; Liver Neoplasms/Liver Neoplasms/Liver Neoplasms/*mortality

Source: Cancer research and treatment [Cancer Res Treat] 2021 Oct; Vol. 53 (4), pp. 1195-1203. Date of Electronic Publication: 2021 Feb 01.Publisher: Korean Cancer Association Country of Publication: Korea (South) NLM ID: 101155137 Publication Model: Print-Electronic Cited Medium: Internet

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

Combination antiangiogenic tyrosine kinase inhibition and anti-PD1 immunotherapy in metastatic renal cell carcinoma: A retrospective analysis of safety, tolerance, and clinical outcomes.

Authors : Laccetti AL; Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Garmezy B

Subjects: Antineoplastic Combined Chemotherapy Protocols/Antineoplastic Combined Chemotherapy Protocols/Antineoplastic Combined Chemotherapy Protocols/*therapeutic use ; Carcinoma, Renal Cell/Carcinoma, Renal Cell/Carcinoma, Renal Cell/*drug therapy ; Kidney Neoplasms/Kidney Neoplasms/Kidney Neoplasms/*drug therapy

Source: Cancer medicine [Cancer Med] 2021 Apr; Vol. 10 (7), pp. 2341-2349. Date of Electronic Publication: 2021 Mar 01.Publisher: John Wiley & Sons Ltd Country of Publication: United States NLM ID: 101595310 Publication Model: Print-Electronic Cited Medium: Internet

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

نتائج البحث

فلترة النتائج

Impact of first-line tyrosine kinase inhibitor selection on survival outcomes with second-line nivolumab in metastatic renal cell carcinoma.

A randomized, open-label, phase 3 trial of pembrolizumab plus epacadostat versus sunitinib or pazopanib as first-line treatment for metastatic renal cell carcinoma (KEYNOTE-679/ECHO-302).

[The efficacy and safety of anlotinib combined with niraparib in treating patients with platinum-resistant recurrent ovarian cancer].

Comparing niraparib versus platinum-taxane doublet chemotherapy as neoadjuvant treatment in patients with newly diagnosed homologous recombination-deficient stage III/IV ovarian cancer: study protocol for cohort C of the open-label, phase 2, randomized controlled multicenter OPAL trial.

Vulnerability to low-dose combination of irinotecan and niraparib in ATM-mutated colorectal cancer.

Effect of Differences in Metabolic Activity of Melanoma Models on Response to Lonidamine plus Doxorubicin.

A single-arm, phase II study of niraparib and bevacizumab maintenance therapy in platinum-sensitive, recurrent ovarian cancer patients previously treated with a PARP inhibitor: Korean Gynecologic Oncology Group (KGOG 3056)/NIRVANA-R trial.

A Phase-2 Trial of Single Agent Axitinib as Maintenance Therapy Following First-Line Treatment With Modified FOLFOX/Bevacizumab in Patients With Metastatic Colorectal Cancer.

Real-World Clinical Outcomes and Prognostic Factors for Patients with Advanced Angiosarcoma who Received Systemic Treatment.

Combination antiangiogenic tyrosine kinase inhibition and anti-PD1 immunotherapy in metastatic renal cell carcinoma: A retrospective analysis of safety, tolerance, and clinical outcomes.

اتصل بنا

اتبع